4 Biotechs That Could Be Potential Acquisition Targets In 2021

Uniqure has a market cap of $2.1 billion. Stock of this Zacks Rank #3 company is down 33.6% year to date.

uniQure N.V. Price

uniQure N.V. Price

uniQure N.V. price | uniQure N.V. Quote

REGENXBIO Inc. (RGNX - Free Report)

The company is a clinical-stage biotechnology company that focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. The company’s most advanced candidate, RGX-314, is being evaluated in a phase I/IIa for treating wet age-related macular degeneration (“AMD”).Apart from RGX-314, the company is also developing three other gene therapy candidates for treating certain rare neurological symptoms.

REGENXBIO’s market cap is $1.6 billion. Currently, the company carries a Zacks Rank #3. So far this year, shares have gained 5.9%.



REGENXBIO Inc. price | REGENXBIO Inc. Quote

Deciphera Pharmaceuticals, Inc. (DCPH - Free Report)

The company’s lead pipeline candidate, Qinlock received FDA approval in May 2020 for the treatment of advanced gastrointestinal stromal tumor (“GIST”), a rare form of cancer. The company is also developing the drug in a late-stage study for treating GIST in a different treatment setting. It also has several pipeline candidates targeting oncology indications.

This Zacks Rank #3 company has a market cap of $3.2 billion. The stock is down 10.5% so far this year.

Deciphera Pharmaceuticals, Inc. Price

Deciphera Pharmaceuticals, Inc. Price

Deciphera Pharmaceuticals, Inc. price | Deciphera Pharmaceuticals, Inc. Quote

1 2 3
View single page >> |

Disclaimer: Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.